In response to the Office Action of April 15, 2004, please amend the application as follows:

IN THE CLAIMS

1. (Currently Amended) A method for [treatment of] treating patients suffering from inflammatory and tumor processes, autoimmune aggression, dystrophy, sclerotic changes and functional disorders using embryonic cell suspensions comprising:

preparing [of] a main suspension containing living embryonic [cells selected from the group consisting of hematopoietic liver cells,] hematopoietic spleen cells, [combination thereof], and a pharmaceutically acceptable liquid medium, 1 ml of said main suspension containing:

a) nucleated cells: $5\text{-}200*10^6$

b) colony-forming units of granuloctye/macrophage (CFU-GM): $20\text{-}200*10^3$

c) colony-forming units of granulocyte, erythrocyte, monocyte/macrophage, and megakaryocyte (CFU GEMM) $0.5\text{-}10*10^3$

d) progenitor cells, CD_{34} (PC CD_{34}) $1\text{-}20*10^6$

and [at least one] administering of [such] at least one said main suspension , prepared *ex tempore* or frozen at cryogenic temperatures and subsequently thawed, to the body of a patient in need of treatment for inflammatory and tumor processes, autoimmune aggression, dystrophy, sclerotic changes and functional disorders,

wherein in addition to the [above] main suspension of [embryonic tissues] at least one additional suspension is prepared, said additional suspension containing living embryonic cells selected from the group consisting of [hematopoietic liver stem cells,] hematopoietic spleen stem cells, hepatocytes, thymocytes, epitheliocytes of the primary

alimentary canal, brain nervous cells, and a combination of cells of at least two of said [kinds] group, and administering at least one said [at least one such] additional suspension, along with the main one, to the patient's body.

2. (Original) The method of claim 1, wherein at least one said additional suspension is administered to the patient's body concurrently with the main suspension.

3. (Original) The method of claim 2, wherein prior to administration to the patient's body, at least one said additional suspension is combined with the main suspension.

4. (Original) The method of claim 1, wherein said main suspension and at least one said additional suspension are administered consecutively to the patient's body.

5. (Original) The method of claim 4, wherein said additional suspension is administered to the patient's body after administering the main suspension.

6. (Original) the method of claim 4, wherein said main suspension is administered to the patient's body after administering the additional suspension.

7. (Original) The method of claim 1, wherein said main and additional suspensions are prepared from tissues of the same embryo.